Related Articles
Anti‑PD‑1/PD‑L1 and anti‑CTLA‑4 associated checkpoint inhibitor pneumonitis in non‑small cell lung cancer: Occurrence, pathogenesis and risk factors (Review)
Characteristics of severe adverse events after peptide vaccination for advanced cancer patients: Analysis of 500 cases
Gut microbiota influences the efficiency of immune checkpoint inhibitors by modulating the immune system (Review)
Immune checkpoint inhibitor‑associated diabetes mellitus in patients with HCC: Report of three cases and literature review
Development of a predictive model for immune‑related adverse events in patients with cancer